PT-141 (bremelanotide) — the melanocortin-pathway research peptide

PT-141 — molecular name bremelanotide — is a synthetic cyclic heptapeptide that activates melanocortin receptors with substantial selectivity for the MC4R subtype expressed in the hypothalamus. It is one of the few research peptides whose academic mechanism literature, animal-model pharmacology, and human clinical-trial development have all converged into a regulatory-approved medicinal indication.

What PT-141 actually is

PT-141 is the research designation for bremelanotide — a cyclic heptapeptide derived from melanotan II via removal of the C-terminal amide group and substitution of one residue. The structural motif at the active site is the His-Phe-Arg-Trp (HFRW) tetrapeptide common to all melanocortin agonists, derived from the natural ligand α-MSH (α-melanocyte stimulating hormone). Molecular weight is approximately 1,025 Da; the compound is supplied as the trifluoroacetate or acetate salt.

The relationship to melanotan II is biologically important. Melanotan II is a broad melanocortin-receptor agonist (MC1R/MC3R/MC4R/MC5R) and produces strong skin-pigmentation effects via MC1R activation. PT-141 has substantially higher selectivity for MC3R and MC4R over MC1R, which is why it does not produce the pigmentary phenotype of melanotan II at therapeutic doses. The mechanism work below explains why the MC4R selectivity is the relevant axis for the clinical-development pathway.

What the mechanism research shows

Two well-replicated mechanism findings:

• MC4R activation in the hypothalamic mPOA. Animal studies have established that PT-141 activates presynaptic MC4R on neurons in the medial preoptic area (mPOA) of the hypothalamus, leading to downstream dopaminergic signalling [1]. This is the central-nervous-system mechanism that distinguishes melanocortin-pathway agonists from peripheral signalling pathways targeted by other research compound classes.
• Neuroendocrine downstream effects. MC4R activation in the hypothalamus modulates dopamine and oxytocin release in specific brain regions. The 2007 melanocortin review consolidates the receptor-level pharmacology and the neuroendocrine cascade [2].

Adjacent mechanism work — energy balance, food intake, and appetite regulation via paraventricular-nucleus MC4R signalling — is well-established for the receptor family but is not the primary focus of the bremelanotide-specific literature.

Honest take: the MC4R selectivity of bremelanotide is one of the cleaner pharmacology stories in the research-peptide category. The molecule does what the receptor pharmacology predicts, replicated across multiple labs.

The clinical-development history

Bremelanotide moved through formal drug-development trials more thoroughly than almost any research peptide on the market. A 2006 phase-2 randomised controlled trial in premenopausal women with sexual-arousal indications established the human pharmacological signal that drove the subsequent clinical program [3]. The molecule was subsequently developed by Palatin Technologies and AMAG Pharmaceuticals through phase-3 trials and received FDA approval in 2019 for a specific clinical indication.

For research-supply purposes, the clinical-development history is relevant context but does not change the regulatory status of the research-grade compound. The approved medicine is a registered prescription product with its own manufacturer, quality-control regime, and clinical-use protocols. The research-grade peptide is supplied lyophilised for non-clinical investigation, with no claim of clinical equivalence to the approved medicine.

The UAE research-supply landscape

PT-141 is supplied in the UAE as a lyophilised powder, most commonly 10 mg per vial. The compound is reasonably stable in dry form when stored at -20°C; reconstituted in bacteriostatic water, it is typically rated for 28 days at 2-8°C. As a cyclic peptide it is more synthesis-intensive than linear peptides of equivalent length, so research-supply purity-control practice varies meaningfully across vendors. The 10 mg research-consultation page covers the lot-specific analytical disclosure framework.

Open questions

Open research questions in the published literature:

• Off-target activity at other MC receptors. PT-141 has substantial MC3R activity in addition to its primary MC4R target; the in-vivo relevance of MC3R activation is less well-characterised.
• Sex-specific pharmacology. The published controlled-trial work has focused on female cohorts; the male pharmacology has been studied but with smaller and less consistent trial designs.
• Subcutaneous vs intranasal vs sublingual administration. The approved medicine uses subcutaneous injection; intranasal formulations have been investigated in academic work but did not advance to commercial development.
• Long-term safety at chronic-administration doses. The approval pathway used on-demand dosing, not chronic daily administration; longer-term studies at frequent administration intervals do not exist.

Further reading

Peer-reviewed citations used inline:

• [1] Clayton, Althof, Kingsberg et al. — Womens Health 2021. The neurobiology of bremelanotide — hypothalamic MC4R + dopaminergic mechanism.
• [2] King, Hu et al. — Eur J Pharmacol 2007. Melanocortins in the treatment of sexual dysfunction — receptor pharmacology + neuroendocrine downstream signalling.
• [3] Diamond, Earle et al. — J Sex Med 2006. Foundational randomised controlled trial establishing the human pharmacological signal for bremelanotide.

Last reviewed 26 May 2026. Wellness Labs supplies PT-141 as research-grade lyophilised powder for non-clinical investigation. The approved prescription medicine containing the same active ingredient is a separate registered product and is not what we sell. Editorial inbox: info@uaewellnesslab.com.